Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Boston Scientific reveals results of the HORIZONS AMI coronary stent system trial

Boston Scientific : 16 October, 2008  (Company News)
Boston Scientific has announced results from an analysis of the HORIZONS AMI trial, which is sponsored by the Cardiovascular Research Foundation (CRF) with research grant support from Boston Scientific and The Medicines Company, and is designed to determine the safety and efficacy of the Taxus Express2 Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI), commonly referred to as a heart attack.
With 3,006 patients enrolled globally, the HORIZONS AMI trial will provide the medical community with critical data from one of the largest randomized clinical trials ever performed in patients with heart attacks. Heart attack patients are often treated with bare-metal stents and are a more complicated patient population at higher risk of death.

'In the HORIZONS AMI trial, the outcomes provide definitive evidence that, in patients with AMI, drug-eluting stents were superior in efficacy to bare-metal stents and had a comparable safety profile at one year,' said Gregg W Stone, MD, CRF chairman, professor of medicine and the director of research and education at the Center for Interventional Vascular Therapy at New York Presbyterian-Hospital/Columbia University Medical Center and principal investigator of the HORIZONS AMI trial.

'Outcomes from prior registry studies of drug-eluting stents compared to bare-metal stents in AMI patients have been conflicting; this is the first prospective, large, international randomised clinical trial and provides conclusive evidence on this subject,' continued Dr Stone. 'The findings from the HORIZONS AMI trial will have a major impact on how decisions are made regarding drug-eluting and bare-metal stents in the highest risk patients in this trial, those in the early hours of a heart attack. The study removes much of the uncertainty and concern about the efficacy and safety of drug-eluting stents in this clinical setting. Moreover, all of the patients in this trial will be followed for five years to ensure that these favourable results are maintained.'

One-year results showed comparable overall safety outcomes (death, stroke, myocardial infarction or Stent thrombosis) between the two treatment groups (8.0 percent for the Express bare-metal Stent versus 8.1 percent for the Taxus Express Stent, p=0.92). There was a statistically significant 41 percent reduction in revascularization in the Taxus Express group (7.5 percent for the Express Stent versus 4.5 percent for the TAXUS Express Stent, p=0.002).

'Our investments in drug-eluting Stent clinical trials are designed to provide the medical community with relevant data they can use in combination with their own clinical judgment to decide optimal treatment strategies for patients,' said Donald S Baim, MD, chief medical and scientific officer of Boston Scientific. 'The HORIZONS trial provides valuable insight into the benefits of the Taxus Express Stent in a high-risk patient population.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo